EUVIMEDEUVIMED entdecken
Open Access

GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study

Helen Tesfaye iD, Julie M Paik, Deborah J Wexler, Jimena Tatiana Hathaway, Elaine W Yu, Ariel Freedman, Joseph F Rizzo, Elisabetta Patorno iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Helen Tesfaye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Optic Neuropathy, Ischemic, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAMS NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Evidence on the safety of semaglutide and other glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) concerning non‐arteritic anterior ischemic optic neuropathy (NAION) is inconclusive, with several studies published to date presenting methodological challenges. We sought to compare the risk of presumed NAION in patients with type 2 diabetes (T2D), initiating a GLP‐1RA versus a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), using a new‐user active comparator cohort study design within a target trial emulation framework. Materials and methods Using insurance claims data from three databases (01/2016–08/2024), we identified 482 912 propensity score matched (1:1) pairs of GLP‐1RA and SGLT2i adult initiators with T2D and without prior ischemic optic neuropathy (ION) or other optic nerve disorders. NAION was defined as a diagnosis of ION without other causes of optic neuropathy, combined with an ophthalmologist or optometrist visit on the same day. We estimated pooled hazard ratios (HRs) and rate differences (RDs).

Results

Over a median follow‐up of 6.7 months on treatment, the risk of incident NAION was higher among initiators of GLP‐1RA compared with SGLT2i [HR, 1.85; 95% CI (1.51–2.27); RD, 0.29 (0.19, 0.39) per 1000 person‐years]. Results were consistent across subgroups and sensitivity analyses. A meta‐analysis of our semaglutide analysis with previously published results also showed an elevated risk, with a HR of 2.78 (1.39–5.56).

Conclusions

In this large observational study, the initiation of GLP‐1RA was associated with an 85% increase in the risk of presumed NAION, compared with the initiation of SGLT2is, though incidence rates and absolute increase in risk were small.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Optic Neuropathy, IschemicSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansFemaleMaleMiddle AgedAgedRisk FactorsGlucagon-Like PeptidesAdultIncidenceGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 analoguepharmacoepidemiologyreal‐world evidencetype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.
  • MGH Diabetes Center, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
  • Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
  • Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Helen Tesfaye, Elisabetta Patorno

Förderung

  • NIDDK NIH HHS
  • NIAMS NIH HHS
  • FDA HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Tesfaye, H., Paik, J. M., Wexler, D. J., Hathaway, J. T., Yu, E. W., Freedman, A., Rizzo, J. F., & Patorno, E. (2026). GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70200

Vancouver

Tesfaye H, Paik JM, Wexler DJ, Hathaway JT, Yu EW, Freedman A, et al. GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70200

BibTeX
@article{Tesfaye2026,
  author = {Tesfaye, Helen and Paik, Julie M and Wexler, Deborah J and Hathaway, Jimena Tatiana and Yu, Elaine W and Freedman, Ariel and Rizzo, Joseph F and Patorno, Elisabetta},
  title = {GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70200}
}
Kostenlos starten →